Want to see MCK full AI Analyst Report?
Revenue by Segment
Shows how revenue is distributed across various business segments, indicating which areas are growing or declining and where the company is focusing its efforts.
McKesson’s revenue mix is changing: U.S. Pharmaceutical remains the steady growth engine, Prescription Technology is a consistent growth contributor, and a new Oncology & Multispecialty line has suddenly become material—matching management’s reorganization and acquisition-driven strategy. International revenue appears to have been reclassified away recently, while Medical‑Surgical is broadly flat and flagged for potential separation, concentrating upside in higher‑margin oncology and tech businesses and underpinning the company’s raised guidance.
MCK Revenue by Segment
| Date | Other | International | U.S. Pharmaceutical | Prescription Technology Solutions | Medical-Surgical Solutions | Oncology & Multispecialty |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | $0.00 | $0.00 | $86.77B | $1.57B | $2.82B | $14.22B |
| Mar 31, 2026 | $101.00M | $0.00 | $79.12B | $1.50B | ― | $12.71B |
| Dec 31, 2025 | $335.00M | $0.00 | $88.32B | $1.50B | $2.99B | $13.01B |
| Sep 30, 2025 | $302.00M | $0.00 | $86.48B | $1.38B | $2.95B | $12.04B |
| Jun 30, 2025 | $0.00 | $3.74B | $89.95B | $1.43B | $2.70B | $0.00 |
| Mar 31, 2025 | $0.00 | $3.46B | $83.17B | $1.34B | $2.85B | $0.00 |
| Dec 31, 2024 | $0.00 | $3.86B | $87.11B | $1.37B | $2.95B | $0.00 |
| Sep 30, 2024 | $0.00 | $3.71B | $85.73B | $1.26B | $2.95B | $0.00 |
| Jun 30, 2024 | $0.00 | $3.69B | $71.72B | $1.24B | $2.64B | $0.00 |
| Mar 31, 2024 | $0.00 | $3.55B | $68.79B | $1.18B | $2.84B | $0.00 |
| Dec 31, 2023 | $0.00 | $3.64B | $73.02B | $1.21B | $3.03B | $0.00 |
| Sep 30, 2023 | $0.00 | $3.48B | $69.77B | $1.14B | $2.83B | $0.00 |
| Jun 30, 2023 | $0.00 | $3.47B | $67.16B | $1.24B | $2.61B | $0.00 |
| Mar 31, 2023 | $0.00 | $3.36B | $61.68B | $1.18B | $2.69B | $0.00 |
| Dec 31, 2022 | $0.00 | $4.45B | $61.93B | $1.12B | $2.99B | $0.00 |
| Sep 30, 2022 | $0.00 | $6.24B | $60.06B | $1.02B | $2.84B | $0.00 |
| Jun 30, 2022 | $0.00 | $6.55B | $56.95B | $1.07B | $2.59B | $0.00 |
| Mar 31, 2022 | $0.00 | $8.53B | $53.68B | $1.02B | $2.87B | $0.00 |
| Dec 31, 2021 | $0.00 | $9.46B | $55.04B | $1.03B | $3.08B | $0.00 |
| Sep 30, 2021 | $0.00 | $9.11B | $53.41B | $932.00M | $3.12B | $0.00 |
| Jun 30, 2021 | $0.00 | $6.55B | $56.95B | $1.07B | $2.59B | $0.00 |
| Mar 31, 2021 | $0.00 | $8.60B | $47.04B | $789.00M | $2.71B | $0.00 |
| Dec 31, 2020 | $0.00 | $9.27B | $49.49B | $777.00M | $3.05B | $0.00 |
| Sep 30, 2020 | $0.00 | $9.54B | $48.07B | $668.00M | $2.53B | $0.00 |
| Jun 30, 2020 | $0.00 | $9.25B | $50.02B | $881.00M | $2.53B | $0.00 |
| Mar 31, 2020 | $0.00 | $9.75B | $45.84B | $736.00M | $2.21B | $0.00 |
| Dec 31, 2019 | $0.00 | $9.86B | $46.45B | $714.00M | $2.14B | $0.00 |
| Sep 30, 2019 | $0.00 | $9.32B | $45.61B | $626.00M | $2.06B | $0.00 |
